Skip to main content
[Preprint]. 2026 May 8:2026.05.01.722263. [Version 2] doi: 10.64898/2026.05.01.722263

Figure 2. Active RE Methylation Subtype Predicts Poorer Survival Independent of Clinical and TME Composition.

Figure 2.

Kaplan–Meier survival curves for RE-defined tumor subgroups (Repressed, Transient, Active). The three subgroups demonstrate a graded survival pattern, with the Repressed group showing the most favorable outcomes, followed by Transient and Active tumors (log-rank p < 0.0001). Median overall survival was 3.7 years for the Active group (95% CI: 2.4–6.1) and 7.0 years for the Transient group (95% CI: 4.5–NA). Median survival was not reached for the Repressed group.